Rainbow Coral, via wholly owned subsidiary Rainbow BioSciences LLC, seeks out new partnerships with biotechnology developers to deliver new medical technologies and innovations to market. The company today reported that one such partner, Nano3D Biosciences (n3D), is positioned to commercialize its BioAssembler product line in the U.S. marketplace through a distribution agreement with St. Louis-based scientific products distributor, MIDSCI.
The BioAssembler is a breakthrough technology that allows researchers to culture cells in three dimensions, creating lifelike tissues similar to those found naturally within the body. Per the agreement, MIDSCI will market and sell BioAssembler technology to life sciences researchers in pharmaceutical, biotech, academic, and government laboratories across the nation.
"With MIDSCI's focus on the cell culture market in the U.S. and the capabilities of its sales and marketing organization in addressing the needs of the life science researchers in a variety of market segments, this distribution partnership will provide even easier access to our 3D cell culture (technology) for researchers in the U.S.," n3D president and CSO Dr. Glauco Souza stated in the press release.
RBCC last year signed a joint-venture agreement with n3D to assist in the development and market the BioAssembler. The company notes heightened interest in n3D's magnetic levitation technology after it was featured in an article in Nature, the world's premiere science journal, and says the new distribution deal will establish even greater visibility.
"This deal with MIDSCI is a major step forward in turning this revolutionary technology into the global standard in cellular research," said RBCC CEO Patrick Brown.
For more information visit RainbowBioSciences.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net